Xarelto in prolonged prophylaxis of recurrent venous thromboembolism

Abstract:

Most patients with VTE (venous thromboembolism) require prolonged thromboprophylaxis of recurrent events. According to the current guidelines, it can be done using vitamin K antagonists (VKA), novel oral anticoagulants (NOAC), parenteral anticoagulants or small doses of acetylsalicylic acid. In clinical trial EINSTEIN CHOICE administration of rivaroxaban 20 mg and 10 mg doses once daily in comparison to acetylsalicylic acid 100 mg once daily for extended prophylaxis of recurrent VTE was investigated for a period of up to 12 months. The risk of recurrent VTE was significantly lower with rivaroxaban 20 mg or 10 mg versus acetylsalicylic acid, with low and similar rates of major bleeding. Based on this study, together with 20 mg dose, rivaroxaban 10 mg was also registered for extended prophylaxis of recurrent VTE. Rivaroxaban treatment is simple to start, with the flexibility of choosing dose based on patient’s individual risk profile in VTE extended treatment.

Key words:
prolonged prophylaxis; recurrent venous thromboembolism; EINSTEIN CHOICE; rivaroxaban